pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Aug 6·1 min read
save

Merck KGaA to receive up to €40 million in US tariff refunds for life science business through 2026

Aug 6, 2026·read at Endpoints ↗RegulatoryPositive

Merck KGaA announced that it expects to receive tariff refunds for its life‑science division after a US Supreme Court ruling.

The company estimates the refunds will total roughly €40 million and will be paid out through the end of 2026.

The refunds arise because the Court blocked several tariffs that had been imposed under the previous administration.

Merck says the reimbursement will help offset costs for its life‑science customers and improve its financial position.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Merck KGaA readies tariff refunds worth €40M for life science customers”

read at Endpoints ↗
82 words · retrieved Aug 6
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Merck KGaA3

related stories

  • 2d agoBMS scraps Orum’s targeted degrader after reviewing Phase 1 dataBioSpace
  • 4d agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Sep 9Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinicEndpoints
  • Sep 9Beeline flies into phase 3 as oral lupus drug soars past placeboFierce Biotech
  • Sep 8Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityFierce Biotech